LUMINARI, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 29.797
EU - Europa 12.820
AS - Asia 12.543
SA - Sud America 2.086
AF - Africa 323
OC - Oceania 89
Continente sconosciuto - Info sul continente non disponibili 10
Totale 57.668
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 29.334
GB - Regno Unito 4.331
CN - Cina 3.424
SG - Singapore 3.354
IT - Italia 2.062
DE - Germania 1.826
HK - Hong Kong 1.760
BR - Brasile 1.576
VN - Vietnam 1.507
SE - Svezia 1.070
FI - Finlandia 796
RU - Federazione Russa 572
FR - Francia 531
UA - Ucraina 524
TR - Turchia 472
KR - Corea 373
IN - India 279
BG - Bulgaria 232
CA - Canada 221
AR - Argentina 198
ID - Indonesia 198
BD - Bangladesh 183
JP - Giappone 167
NL - Olanda 162
MX - Messico 131
IQ - Iraq 125
IE - Irlanda 102
ES - Italia 100
ZA - Sudafrica 90
AE - Emirati Arabi Uniti 86
EC - Ecuador 84
IL - Israele 84
PL - Polonia 83
AU - Australia 80
PK - Pakistan 79
MA - Marocco 67
AT - Austria 65
CO - Colombia 60
EG - Egitto 52
CH - Svizzera 49
SA - Arabia Saudita 47
VE - Venezuela 44
CL - Cile 42
PH - Filippine 39
PT - Portogallo 39
BE - Belgio 38
MY - Malesia 38
UZ - Uzbekistan 38
LT - Lituania 37
TH - Thailandia 34
JO - Giordania 33
CZ - Repubblica Ceca 31
IR - Iran 30
KE - Kenya 30
PY - Paraguay 30
TW - Taiwan 29
RO - Romania 28
NP - Nepal 25
BZ - Belize 23
DZ - Algeria 23
AZ - Azerbaigian 21
DO - Repubblica Dominicana 18
PE - Perù 18
BO - Bolivia 17
CR - Costa Rica 17
OM - Oman 16
TN - Tunisia 16
DK - Danimarca 15
AL - Albania 14
LB - Libano 14
UY - Uruguay 14
KG - Kirghizistan 13
KZ - Kazakistan 13
NO - Norvegia 13
BH - Bahrain 12
HU - Ungheria 12
BY - Bielorussia 11
PA - Panama 11
GR - Grecia 9
LV - Lettonia 9
RS - Serbia 9
SK - Slovacchia (Repubblica Slovacca) 9
AM - Armenia 8
JM - Giamaica 8
NZ - Nuova Zelanda 8
HR - Croazia 7
QA - Qatar 7
SI - Slovenia 7
SN - Senegal 7
EE - Estonia 6
ET - Etiopia 6
GE - Georgia 6
HN - Honduras 6
LU - Lussemburgo 6
NG - Nigeria 6
CY - Cipro 5
PR - Porto Rico 5
SV - El Salvador 5
TT - Trinidad e Tobago 5
BF - Burkina Faso 4
Totale 57.580
Salva come PNG Salva come JPEG
Città #
Fairfield 3.243
Southend 3.027
Ashburn 2.898
Santa Clara 2.558
Singapore 2.103
Woodbridge 1.850
Hong Kong 1.736
Houston 1.452
Chandler 1.210
Seattle 1.185
Wilmington 1.117
Cambridge 1.064
Frankfurt am Main 1.057
Hefei 997
Jacksonville 928
San Jose 861
Dearborn 813
Ann Arbor 785
Beijing 704
London 654
Chicago 636
Nyköping 605
Helsinki 583
Los Angeles 528
Ho Chi Minh City 515
The Dalles 391
Council Bluffs 356
Hanoi 333
Seoul 313
San Diego 310
New York 286
Modena 262
Princeton 238
Sofia 225
Salt Lake City 221
Izmir 209
Redwood City 193
Shanghai 190
Eugene 186
São Paulo 177
Lauterbourg 174
Buffalo 167
Milan 165
Dallas 162
Moscow 141
Manchester 139
Jakarta 135
Rome 118
Munich 104
Elk Grove Village 102
Dublin 91
Tampa 91
Tokyo 89
Columbus 85
Phoenix 77
Da Nang 75
Bologna 74
Bremen 72
Orem 63
Dong Ket 62
Sterling 62
Warsaw 62
Falls Church 59
Guangzhou 58
Yavné 55
Des Moines 54
Boardman 53
Brooklyn 52
Chennai 52
Rio de Janeiro 52
Haiphong 51
San Francisco 49
Toronto 49
Lancaster 48
Montreal 47
Turin 47
Atlanta 46
Amsterdam 45
Stockholm 45
Istanbul 43
Philadelphia 43
Denver 42
Mexico City 42
Tappahannock 42
Baghdad 41
Nuremberg 41
Miami 39
Norwalk 39
Dulles 38
Kilburn 38
Kent 36
Turku 36
Redondo Beach 35
Tashkent 34
Belo Horizonte 33
Dhaka 33
Johannesburg 33
Brussels 31
Sydney 31
Casablanca 30
Totale 40.951
Salva come PNG Salva come JPEG
Nome #
Survival of cancer patients in Italy [La sopravvivenza dei pazienti oncologici in Italia [La sopravvivenza dei pazienti oncologici in Italia] 856
Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: Final results of a multicenter phase II study 778
Veno-occlusive disease nurse management: Development of a dynamic monitoring tool by the GITMO nursing group 683
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 679
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma 619
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 512
T-cell lymphoma in South America and Europe. 491
Il linfoma mantellare 485
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 484
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 464
Nonpegylated liposomal doxorubicin (Myocet) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EURO 18 trial 437
Transformed follicular lymphoma 431
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 423
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. 404
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 398
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. 392
Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions. 390
Use of 2-(18F)fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy 374
Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma 373
Treatment of indolent B-cell nonfollicular lymphomas: Final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi 370
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: Results from the Fondazione Italiana Linfomi MCL-0208 trial 365
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy 361
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi 356
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfom 352
Prognosis of follicular lymphomas 350
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 346
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study 332
Pure red-cell aplasia and epoetin therapy 330
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: Results of a prospective, multicenter study of the Gruppo Italiano per lo Studio dei Linfomi (GISL) 329
Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project 326
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 325
PET-CT for staging and early response: Results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study 318
A Gene Expression–based Model to Predict Metabolic Response after Two Courses of ABVD in Hodgkin Lymphoma Patients 316
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study 309
Anthracyclines: A cornerstone in the management of non-Hodgkin's lymphoma 308
Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies 307
Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi 306
Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 306
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study 304
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma 304
Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias 304
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 302
Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients 301
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 299
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 298
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies 298
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi 297
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 297
Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy 296
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 296
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection 295
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 295
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. 294
Dismal outcome of t-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry 293
The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL) 287
Role of Glutathione-S-Transferase (GST) polymorphisms in patients with advanced Hodgkin Lymphoma: results from the HD2000 GISL Trial 285
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi 283
High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi Study 282
Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pilori interventions: results from a population-based study on extranodal marginal zone lymphomas 281
Bendamustine salvage therapy for T cell neoplasms 280
ABVD versus Stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial 279
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials 279
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 276
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL) 273
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) InfectionBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3054 272
Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi 272
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi 271
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study 271
Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi 270
High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results. 270
Efficacy Controls and Long-Term Follow-Up of Patients (Pts) Treated with FC Plus Rituximab for Relapsed Follicular NHL. Session Type: Publication Only 268
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 268
Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma 267
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi 267
Watchful waiting in low-tumorburden follicular lymphoma in the Rituximab era. Results of a F2 observational 266
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 266
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 264
The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL) 264
Reply to H.J.A. Adams et al and E. Laffon et al 262
I tumori in Italia. Rapporto 2011: La sopravvivenza dei pazienti oncologici in Italia 262
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma 260
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study 260
Advances in Treatment of Follicular Lymphoma 260
Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy. 257
CLIPI: a new prognostic index for indolent cutaneos B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 257
Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients 256
Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. 256
Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study 255
Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide - Response to Mileshkin et al. 253
Phase II Study with Fludarabine and Cyclophosphamide Plus Rituximab (FC+R) in Relapsed Follicular Lymphoma Patients. 252
The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi 252
Reply to T.P. Vassilakopoulos et al 252
Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL) 251
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia 250
Analysis of BCL-10 gene mutations in ovarian cancer cell lines. 248
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale 247
Prognostic tools in follicular lymphomas 244
Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi. 244
A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular non-Hodgkin's Lymphoma 243
The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study 242
Totale 32.882
Salva come PNG Salva come JPEG
Categoria #
all - tutte 227.660
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 227.660
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.549 0 0 0 0 0 0 0 0 0 664 495 390
2021/20224.667 325 538 521 270 134 271 245 297 471 365 804 426
2022/20233.849 419 393 324 330 460 504 96 396 465 97 220 145
2023/20244.005 113 207 185 229 1.442 205 411 669 78 79 89 298
2024/20259.509 313 88 141 700 1.717 1.465 723 509 1.275 557 929 1.092
2025/202617.187 1.150 893 1.690 2.483 3.003 1.416 2.386 989 1.750 1.427 0 0
Totale 58.307